Raymond James Financial’s Inozyme Pharma INZY Stock Holding History

Raymond James Financial’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-10,419	Closed	-$41.7K	–	5823
2025 Q2	$41.7K	Sell	10,419 -87,412	-89%	-$216K	﹤0.01%	5261
2025 Q1	$89K	Buy	97,831 +23,666	+32%	+$32.8K	﹤0.01%	4560
2024 Q4	$205K	Buy	+74,165	New	+$282K	﹤0.01%	4394

Raymond James Financial's INZY Position: Q3 2025 in Review

Raymond James Financial sold out of Inozyme Pharma (INZY) in Q3 2025, closing a stake of 10,419 shares — an estimated $41.7K sold.

Raymond James Financial first reported a position in INZY in Q4 2024 and held it in 3 quarters. The position peaked at $205K in Q4 2024. 0 funds tracked by Wall St. Rank hold INZY as of Q3 2025.

Raymond James Financial reported no remaining Inozyme Pharma position as of Q3 2025 after selling out during the quarter.
Raymond James Financial sold 10,419 Inozyme Pharma shares in Q3 2025, an estimated $41.7K.
Raymond James Financial first reported a position in Inozyme Pharma in Q4 2024 and held it in 3 quarters.
Raymond James Financial's Inozyme Pharma position peaked at $205K in Q4 2024.
0 funds tracked by Wall St. Rank held Inozyme Pharma as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.